Published in Vasc Health Risk Manag on January 01, 2006
An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog. Vasc Health Risk Manag (2010) 0.90
Insulin detemir for the treatment of obese patients with type 2 diabetes. Diabetes Metab Syndr Obes (2012) 0.79
Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia. Vasc Health Risk Manag (2009) 0.78
Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism. Sci Rep (2016) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Insulin analogues. N Engl J Med (2005) 12.24
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes (2000) 3.74
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes (2004) 3.66
Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care (2000) 2.58
Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA (2003) 2.11
Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care (2000) 2.08
Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care (2004) 1.96
The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res (2004) 1.96
Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care (1999) 1.90
A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care (2005) 1.82
Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia (2004) 1.75
Insulin: discovery and controversy. Clin Chem (2002) 1.64
Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract (2004) 1.60
Type III allergy to insulin detemir. Diabetes Care (2005) 1.50
Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther (2004) 1.36
Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab (2005) 1.30
The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther (2004) 1.30
Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care (2003) 1.18
Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins. Postgrad Med J (1988) 1.17
Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes Relat Metab Disord (2004) 1.08
Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs (2004) 1.06
Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia (2005) 1.06
Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care (2001) 1.05
At last, a weight neutral insulin? Int J Obes Relat Metab Disord (2004) 1.03
Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care (2003) 1.02
Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med (2005) 0.98
A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs (2005) 0.97
Severe injection site reaction to insulin detemir. Diabetes Care (2006) 0.79
Spotlight on insulin detemir in type 1 and 2 diabetes mellitus. BioDrugs (2005) 0.79
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care (2008) 2.00
Prevalence of the metabolic syndrome in Luxembourg according to the Joint Interim Statement definition estimated from the ORISCAV-LUX study. BMC Public Health (2011) 1.11
Issues in performing a network meta-analysis. Stat Methods Med Res (2012) 1.03
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension (2003) 0.98
Acanthosis nigricans associated with insulin resistance : pathophysiology and management. Am J Clin Dermatol (2004) 0.98
Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens (2004) 0.94
Efficacy and safety of the weight-loss drug rimonabant. Lancet (2008) 0.91
Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages. J Lipid Res (2013) 0.91
Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens (2008) 0.87
Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab (2010) 0.86
Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood. J Clin Endocrinol Metab (2002) 0.80
[Chronic liver diseases and diabetes]. Rev Med Suisse (2014) 0.79
Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates. Acta Cardiol (2008) 0.78
Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens (2007) 0.77
Obese subjects involvement in a population-based survey: the use of information and communication technologies (ICT) to avoid stigmatization. Qual Life Res (2014) 0.77
The skin landscape in diabetes mellitus. Focus on dermocosmetic management. Clin Cosmet Investig Dermatol (2013) 0.77
Critical assessment of diabetic xerosis. Expert Opin Med Diagn (2012) 0.76
Facing up to the imperceptible perspiration. Modulatory influences by diabetic neuropathy, physical exercise and antiperspirant. Skin Res Technol (2011) 0.75